Phibro Animal Health

PAHC

Market cap $1.6B

Phibro (PAHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Phibro (PAHC) possesses solid growth attributes, which could help it handily outperform the market.

Investors looking for stocks in the Medical - Products sector might want to consider either Phibro Animal Health (PAHC) or Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

PAHC and others highlight how PEG-based GARP picks blend value and growth as markets hit 2026 highs amid rate uncertainty and valuation sensitivity.

RNR, GLDD and PAHC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 2, 2026.

MU, CMC and ALL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 30, 2025.

Phibro (PAHC) could produce exceptional returns because of its solid growth attributes.

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?